Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its…
<!-- Name:DistributionId Value:8751468 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Jasper Therapeutics
Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the…
Three abstracts highlight the safety and efficacy of briquilimab combined with low-toxicity radiation conditioning to achieve full donor engraftment and leukemia disease eradication Data…
Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab…
REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic cell…
Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored…
REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today…
Jasper Therapeutics to Present at Upcoming Conferences
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today…
Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel…
JSP191 is currently being evaluated in four ongoing clinical studies in allogeneic hematopoietic stem cell transplant in patients with Acute Myeloid Leukemia (AML) / Myelodysplastic…
Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines…
REDWOOD CITY, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today…
Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as…
JSP191 is well tolerated with no treatment-related severe adverse events in 24 patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in Ph1b dose expansion study24 of…
Jasper Therapeutics to Host In-Person Key Opinion Leader Webinar on Transforming…
REDWOOD CITY, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today…
Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation…
JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in Ph1b dose expansion study17 of…